New Data from the Phase II ARCHER Trial Demonstrate CardiolRx(TM) Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions
Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with acute myocarditis.Results provide clinical evidence that CardiolRx™ reduces inflammation-driven structural damage in the heart, an important cause of heart failure progression.The ARCHER data strengthen the scientific and clinical rationale for Cardiol's lead Phase III program in recurrent pericarditis (MAVERIC) and support broader development across inflammatory cardiac conditions.Chronic inflammation is a...
2025-12-01 7:27 AM EST
Cardiol Therapeutics Receives U.S. Patent Allowance Broadly Protecting its Heart Drugs to Late 2040
Once issued, this new U.S. patent covers the use of CardiolRx™ and CRD-38 for a broad range of cardiac disorders, including atherosclerosis and heart failure, significantly expanding intellectual property protection in the world's largest pharmaceutical market.This allowance fortifies Cardiol's global intellectual property portfolio, adding to granted and pending patent applications in Europe, Japan, Canada, Australia, and China.Toronto, Ontario--(Newsfile Corp. - November 13, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company...
2025-11-13 7:45 AM EST
Cardiol Therapeutics' Phase II ARCHER Trial Results to be Presented at the European Society of Cardiology Scientific Meeting on Myocardial & Pericardial Diseases
The ESC M&PD meeting brings together the world's experts working to improve the treatment of myocarditis and pericarditis.Presentation to provide comprehensive findings from the ARCHER trial following the reporting of topline results demonstrating a notable improvement in extracellular volume and a significant reduction in left ventricular mass.The Company will host a webcast conference call on December 1, 2025, to discuss the ARCHER findings and their significance, and to highlight the positive implications for Cardiol's programs in inflammatory heart disease.Toronto, Ontario--(Newsfile...
2025-11-05 7:45 AM EST
Cardiol Therapeutics Completes US$11.4 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions advancing with leading pharmaceutical companies.Toronto, Ontario--(Newsfile Corp. -...
2025-10-21 7:27 AM EDT
Cardiol Therapeutics Secures US$11 Million Financing and Extends Cash Runway into Q3 2027
MAVERIC Phase III pivotal trial of orphan drug candidate CardiolRx™ in recurrent pericarditis is fully funded through to a planned New Drug Application submission with the FDA.New data from the ARCHER trial, highlighting the magnitude of reduction in left ventricular (LV) mass and the read through to heart failure, to be presented at a cardiology conference in November 2025.Next-generation therapy CRD-38 for heart failure funded through to clinical development, with partnership discussions advancing with leading pharmaceutical companies.Toronto, Ontario--(Newsfile Corp. -...
2025-10-17 4:34 PM EDT
Cardiol Therapeutics to Participate in Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference
Toronto, Ontario--(Newsfile Corp. - August 11, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will participate in a Fireside Chat at Canaccord Genuity's 45th Annual Growth Conference in Boston, MA, on August 12, 2025, at 9:30 a.m. EDT.A live webcast of the Fireside Chat will be accessible under "Events & Presentations"...
2025-08-11 7:27 AM EDT
Cardiol Therapeutics Announces Topline Results from the Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
Change in the primary endpoint of left ventricular (LV) extracellular volume (ECV) showed a notable improvement (p = 0.0538) favouring CardiolRx™ over placebo.Reduction in ECV was associated with improvements across multiple pre-specified cardiac magnetic resonance imaging (CMR) endpoints, including a significant reduction in LV mass.The ARCHER trial results provide compelling clinical proof of concept for CardiolRx™ and strongly support advancing the clinical development of CardiolRx™ and CRD-38 in cardiomyopathies, heart failure, and myocarditis.The ARCHER results have been submitted for presentation...
2025-08-06 7:27 AM EDT
Cardiol Therapeutics Announces Database Lock for Phase II ARCHER Trial of CardiolRx(TM) in Acute Myocarditis
ARCHER is designed to assess the impact of CardiolRx™ on cardiac magnetic resonance imaging parameters that measure heart dysfunction and edema/fibrosis-key measurements used to predict prognosis in myocarditis patients.Acute myocarditis is a potentially life-threatening condition affecting the heart muscle (myocardium) and is characterized by chest pain, shortness of breath, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness, and can lead to heart failure or sudden cardiac death.There are no FDA-approved drug therapies indicated for the treatment of acute myocarditis.Topline results...
2025-07-22 7:27 AM EDT
Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders
Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces the results from its Annual General Meeting of Shareholders (the "AGM") held virtually via live audio webcast on May 28, 2025. Shareholders voted overwhelmingly in favour of all Management resolutions proposed in the Company's Management Information Circular dated April 10, 2025.Resolutions proposed...
2025-05-29 7:27 AM EDT
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT
Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General Meeting of Shareholders (the "AGM") will be webcast on May 28, 2025, at 4:30 p.m. EDT.Cardiol Therapeutics' 2025 AGMWhen: May 28, 2025, at 4:30 p.m. EDTWhere: Virtual meeting only via live audio webcast online at: web.lumiagm.com/226536161Additional...
2025-05-27 7:27 AM EDT
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors
Toronto, Ontario--(Newsfile Corp. - April 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced that pharmaceutical industry veteran Timothy J. Garnett, M.D., has been nominated to stand for election to the Company's Board of Directors at its 2025 Annual General Meeting of shareholders to be held on May 28, 2025.Dr. Garnett is a distinguished pharmaceutical...
2025-04-29 7:27 AM EDT
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis
Designed to assess the impact of CardiolRx™ on preventing episodes of recurrent pericarditis, the first patient has been randomized by Northwestern University in Chicago.Based on a successful end-of-Phase II meeting with the US FDA and subject to MAVERIC outcomes, Cardiol believes the results from MAVERIC will support a New Drug Application.Data from Cardiol's Phase II MAvERIC-Pilot study presented at the American Heart Association Scientific Sessions 2024 showed that pericarditis patients treated with CardiolRx™ experienced marked and rapid reductions in pericarditis...
2025-04-16 7:27 AM EDT
Cardiol Therapeutics Announces Year-End 2024 Update on Operations
Reported positive data from the Phase II MAvERIC-Pilot study investigating the impact of CardiolRx™ administered to patients with symptomatic recurrent pericarditis; results support advancing to the Phase III MAVERIC trialCompleted patient enrollment in the Phase II ARCHER trial evaluating CardiolRx™ in patientswith acute myocarditis, with topline data expected in Q2 2025CardiolRx™ granted U.S. FDA Orphan Drug Designation for the treatment of pericarditis,which includes recurrent pericarditisCash and cash equivalents of $30.6 million as of December 31, 2024,to fund operations into Q3...
2025-04-01 7:27 AM EDT
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference
Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the TD Cowen 45th Annual Health Care Conference in Boston, MA, on March 5, 2025, at 11:10 a.m. EST.A replay of the live webcast of the presentation will be available under "Events & Presentations"...
2025-03-03 7:27 AM EST
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure
Toronto, Ontario--(Newsfile Corp. - February 20, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announced today the publication of research in the Journal of the American College of Cardiology: Basic to Translational Science ("JACBTS"), titled "Cannabidiol Prevents Heart Failure Dysfunction and Remodeling Through Preservation of Mitochondrial Function and Calcium Handling" (www.jacc.org/doi/abs/10.1016/j.jacbts.2024.12.009). This research was conducted by scientists...
2025-02-20 7:27 AM EST
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
Toronto, Ontario--(Newsfile Corp. - February 4, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that it will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025, at 4:00 p.m. EST.A live webcast of the presentation will be available under "Events & Presentations" in...
2025-02-04 7:27 AM EST
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially reduced MAvERIC-Pilot results support advancing CardiolRx™ into the Phase II/III MAVERIC-2and the Phase III MAVERIC-3 clinical trialsToronto, Ontario--(Newsfile Corp. - November 18, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today reported...
2024-11-18 11:37 AM EST
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis
Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced plans to expand the MAVERIC clinical development program and advance CardiolRx™ into a late-stage clinical trial ("MAVERIC-2") to evaluate the impact of CardiolRx™ in recurrent pericarditis patients following cessation of interleukin-1 ("IL-1") blocker therapy. MAVERIC-2 is...
2024-10-22 6:30 AM EDT
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option
Oakville, Ontario--(Newsfile Corp. - October 11, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, is pleased to announce that, further to its successfully completed public offering of an aggregate of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share...
2024-10-11 8:39 AM EDT
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares
Oakville, Ontario--(Newsfile Corp. - October 10, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, confirmed today that it has successfully closed its previously announced public offering (the "Offering") of 8,437,500 Class A common shares of the Company (the "Common Shares") at a price to the public of US$1.60 per Common Share for...
2024-10-10 9:09 AM EDT